AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31637669
Drug: Olaparib (capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib (capsule and tablet formulations) using intermittent schedules (2 to 10 days of a 21-day cycle) combined with carboplatin/paclitaxel
Trial: 31638652
Drug: Rivaroxaban 15
RxNorm normalized name: rivaroxaban 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 15 mg
Trial: 31639039
Drug: Avelumab (MSB0010718C)
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab (MSB0010718C) at doses of 10 mg/kg to 20 mg/kg every 2 weeks until disease progression or intolerable side effects
Trial: 31639692
Drug: Mutant 4D4
RxNorm normalized name: STREPTOCOCCUS MUTANS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mutant 4D4 (L3-2) antibody-assisted assay
Trial: 31640565
Drug: Postoperative patient-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative patient-controlled intravenous analgesia (PCIA) with 0.2 mg/kg hydromorphone and 4 mg/kg flurbiprofen; pump programmed as 2.0 mL/h background infusion with a loading dose of 1 mL and a lockout period of 15 min
Trial: 31640565
Drug: Postoperative patient-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative patient-controlled intravenous analgesia (PCIA)
Trial: 31640741
Drug: Toothpaste containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toothpaste containing 0.454% w/w stannous fluoride (1100 ppm fluoride), used twice daily for 24 weeks
Trial: 31641633
Drug: Saxagliptin as
RxNorm normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saxagliptin as add-on to metformin
Trial: 31644328
Drug: MRD-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRD-based treatment stratification after induction treatment
Trial: 31644328
Drug: Intensified treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified treatment directly after induction for very poor responders
Trial: 31644380
Drug: Urban Zen
RxNorm normalized name: Geum urbanum root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urban Zen Integrative Therapy
Trial: 31647026
Drug: Atezolizumab monotherapy
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab monotherapy for 1 year
Trial: 31647026
Drug: Experimental vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental vaccine
Trial: 31648294
Drug: CD19-directed chimeric
RxNorm normalized name: DIRECT BLUE 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD19-directed chimeric antigen receptor-modified T (CAR-T) cells, 2 × 10^6 cells per kilogram after lymphodepletion with cyclophosphamide and fludarabine
Trial: 31648999
Drug: Osimertinib at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osimertinib at the dose of 80 mg/d
Trial: 31649017
Drug: Household contacts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Household contacts exposed to drug sensitive tuberculosis
Trial: 31650066
Drug: TetMYB vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TetMYB vaccine
Trial: 31650066
Drug: TetMYB vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TetMYB vaccine and Anti-PD-1 antibody
Trial: 31650077
Drug: Innovative combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Innovative combination intervention to improve access to pediatric cancer services and treatment adherence
Trial: 31650176
Drug: High-dose cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cyclophosphamide (HD-Cy) (3 g/m2)
Trial: 31650176
Drug: Low-dose cyclophosphamide
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cyclophosphamide (LD-Cy) (≤1.5 g/m2)
Trial: 31650176
Drug: CD19-specific CAR
RxNorm normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD19-specific CAR T-cell therapy
Trial: 31650176
Drug: Dose intensity
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose intensity of conditioning chemotherapy and minimal pretreatment disease burden
Trial: 31650393
Drug: Age, diabetes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Age, diabetes duration, BMI, HbA1c, use of metformin, sulfonylurea derivatives, and DPP4 inhibitors
Trial: 31651278
Drug: Simulated interventions
RxNorm normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simulated interventions (e.g., iron fortification)
Trial: 31651359
Drug: Avelumab 10
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab 10 mg/kg intravenous infusion every 2 weeks (1 L subgroup)
Trial: 31651359
Drug: Avelumab 10
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab 10 mg/kg intravenous infusion every 2 weeks (2 L subgroup)
Trial: 31651364
Drug: Standardized oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized oral care bundle (oral assessment, tooth brushing, moisturization, and secretion removal)
Trial: 31651364
Drug: Oral chlorhexidine
RxNorm normalized name: chlorhexidine Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral chlorhexidine
Trial: 31651951
Drug: Oral anticoagulant
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulant (OAC) use
Trial: 31651951
Drug: Non-vitamin K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-vitamin K antagonist oral anticoagulants (NOACs) use
Trial: 31651951
Drug: Antiplatelet monotherapy
RxNorm normalized name: simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet monotherapy
Trial: 31652009
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron supplementation starting at 65 mg daily, titrated based on fasting serum iron concentration.
Trial: 31652392
Drug: Posttransplant DAA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posttransplant DAA therapy for viremic patients
Trial: 31652997
Drug: RC28-E (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RC28-E (5 mg/kg, 15 mg/kg, and 50 mg/kg, ip. Tiw × 9)
Trial: 31652997
Drug: Mono-target antagonist
RxNorm normalized name: tiotropium bromide mono
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mono-target antagonist treatment (VEGF or FGF blocking)
Trial: 31654285
Drug: Everolimus 5
RxNorm normalized name: everolimus 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 5 mg PO daily and panobinostat 10 mg PO 3 times weekly (weeks 1 and 2) given in 21-day cycles
Trial: 31654285
Drug: Everolimus/panobinostat therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus/panobinostat therapy
Trial: 31655936
Drug: telotristat ethyl
RxNorm normalized name: Telotristat ethyl
DrugBank: Telotristat ethyl (DB12095)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: telotristat ethyl treatment
Trial: 31657648
Drug: Fibroblast Growth
RxNorm normalized name: Fibroblast growth factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibroblast Growth Factor Receptor Inhibitors
Trial: 31659739
Drug: Anticoagulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulation therapy (AT)
Trial: 31660391
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (maintained serum 25(OH)D >30 ng/mL)
Trial: 31660640
Drug: Tofacitinib de-escalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib de-escalation (from 10 mg b.d. to 5 mg b.d.)
Trial: 31660640
Drug: Tofacitinib escalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib escalation (from 5 mg b.d. to 10 mg b.d.)
Trial: 31660992
Drug: Curative surgery
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Curative surgery for rectal adenocarcinoma
Trial: 31661530
Drug: Skhokho intervention,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skhokho intervention, details on dosage and duration not available
Trial: 31662377
Drug: MD Anderson
RxNorm normalized name: miconazole nitrate Topical Solution [Nail MD]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MD Anderson Symptom Inventory-Lung Cancer Module (MDASI-LC) for symptom data collection preoperatively, daily postoperatively during in-hospital stay, and weekly after discharge until 4 weeks or start of postoperative oncological therapy.
Trial: 31662801
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide extended release (TA-ER) 32 mg into each knee (total 64 mg)
Trial: 31662801
Drug: Traditional triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional triamcinolone acetonide crystalline suspension (TAcs) 40 mg into each knee (total 80 mg)
Trial: 31663465
Drug: Sarilumab 200
RxNorm normalized name: SARILUMAB 200MG/1.14ML INJ SYR 1.14ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarilumab 200 mg + methotrexate
Trial: 31663906
Drug: Wireless motility
RxNorm normalized name: careless weed pollen extract
DrugBank: Amaranthus palmeri pollen (DB10459)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wireless motility capsules (WMC)
Trial: 31665141
Drug: Heat-stable toxin-based
RxNorm normalized name: (9-L-TYROSINE)HEAT-STABLE ENTEROTOXIN (ESCHERICHIA COLI)-(6-19)-PEPTIDE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat-stable toxin-based vaccine candidates, dosage and duration not specified
Trial: 31665349
Drug: Graded IV
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Graded IV glucose infusion
Trial: 31666082
Drug: Subcutaneous EEG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous EEG
Trial: 31666237
Drug: naproxen 750
RxNorm normalized name: naproxen 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naproxen 750 mg immediately then 250 mg every 8 hours for 7 days
Trial: 31666237
Drug: low-dose colchicine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: low-dose colchicine 500 mcg three times per day for 4 days
Trial: 31667659
Drug: Olaparib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib (100 mg bid) + Carboplatin (AUC 4)
Trial: 31667696
Drug: Conventional-dose oseltamivir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional-dose oseltamivir (75 mg for adolescents/adults; 30-75 mg by body weight for children), twice daily for 10 days
Trial: 31667696
Drug: Double-dose oseltamivir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-dose oseltamivir (150 mg for adolescents/adults; 60-150 mg for children), twice daily for 10 days
Trial: 31667696
Drug: Conventional-dose oseltamivir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional-dose oseltamivir
Trial: 31667696
Drug: Double-dose oseltamivir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-dose oseltamivir
Trial: 31668348
Drug: Iron deficiency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron deficiency (ferritin <100 μg L)
Trial: 31668516
Drug: Patient decision
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient decision aid for medication treatment for opioid use disorder (PtDA-MOUD)
Trial: 31668825
Drug: Geriatric assessment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Geriatric assessment (GA) administered prior to induction and prior to post-remission therapy
Trial: 31668830
Drug: THC (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC (15 mg oral)
Trial: 31669155
Drug: Lorlatinib 100
RxNorm normalized name: lorlatinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorlatinib 100 mg once daily (escalating doses of 10 mg once daily to 100 mg twice daily in phase 1 only)
Trial: 31670288
Drug: Phosphorus-32 microparticles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphorus-32 microparticles with EUS guidance in combination with gemcitabine ± nab-paclitaxel
Trial: 31670431
Drug: Mobile phone-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile phone-based reporting of health-related quality of life (HRQOL) using FACT-G
Trial: 31671877
Drug: Dose Intensive
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose Intensive Rituximab and High-Dose Methylprednisolone
Trial: 31672144
Drug: BSL ≥
RxNorm normalized name: Baseline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BSL ≥ 11.1 mmol/L
Trial: 31672144
Drug: BSL <
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BSL < 6.0 mmol/L or 6.0-11.1 mmol/L
Trial: 31672148
Drug: PCSK9 quartile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCSK9 quartile I (< 136 ng/mL)
Trial: 31672148
Drug: PCSK9 quartile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCSK9 quartile IV (> 266 ng/mL)
Trial: 31672853
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PIVKA-II and AFP
Trial: 31673295
Drug: 100-µg vitamin
RxNorm normalized name: vitamin E 100 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100-µg vitamin D for 3 months
Trial: 31673393
Drug: USPIO (ferumoxytol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: USPIO (ferumoxytol, 4 mg/kg) infusion
Trial: 31673415
Drug: Sarilumab 200
RxNorm normalized name: SARILUMAB 200MG/1.14ML INJ SYR 1.14ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarilumab 200 mg subcutaneously once every 2 weeks
Trial: 31673426
Drug: Stereotactic body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic body radiotherapy (SBRT) delivered to the target lesion with a cumulative dose of 114 Gy (equivalent dose in 2 Gy with an alpha to beta ratio of 2.6).
Trial: 31675952
Drug: Capecitabine 850
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 850 mg/m2, P.O. bid, days 1-14, and ziv-aflibercept 6 mg/kg I.V., day 1, of each 21-day cycle
Trial: 31676359
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CA19-9 and CEA
Trial: 31676359
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CA19-9 and CA-125
Trial: 31676359
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CA19-9 and thrombospondin-2
Trial: 31678771
Drug: Everolimus after
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus after hepatic arterial embolisation therapy (HAET)
Trial: 31679129
Drug: New injectable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New injectable treatment for T2DM
Trial: 31679507
Drug: PAHEPI program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAHEPI program (Treatment 1)
Trial: 31679507
Drug: PAHEPI +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAHEPI + school meals (Treatment 2)
Trial: 31682550
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg once every 3 weeks for 2 years or until disease progression, unacceptable toxicity, or patient withdrawal
Trial: 31684094
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose (HD) intravenous furosemide (greater than 125 mg)
Trial: 31684094
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose (LD) intravenous furosemide (less than 125 mg)
Trial: 31684877
Drug: Anesthesia induction
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anesthesia induction with midazolam, sufentanil, and rocuronium, followed by sevoflurane, with positive pressure ventilation (PEEP 5, tidal volume 6-8 ml/kg)
Trial: 31684927
Drug: Curcumin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin (400 mg in enhanced absorption formulation)
Trial: 31685467
Drug: Target-Controlled Infusion
RxNorm normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Target-Controlled Infusion (TCI) of cefepime, median duration of 4.5 days, targeting a blood concentration of 16 mg/liter
Trial: 31685468
Drug: Telavancin; specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telavancin; specific dosage and duration not mentioned
Trial: 31685476
Drug: Artefenomel and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artefenomel and DSM265 combination treatment
Trial: 31685491
Drug: Loncastuximab tesirine
RxNorm normalized name: Loncastuximab tesirine
DrugBank: Loncastuximab tesirine (DB16222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loncastuximab tesirine at doses 15 to 200 μg/kg every 3 weeks
Trial: 31685491
Drug: Loncastuximab tesirine
RxNorm normalized name: Loncastuximab tesirine
DrugBank: Loncastuximab tesirine (DB16222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loncastuximab tesirine at doses ≥120 μg/kg
Trial: 31685491
Drug: Loncastuximab tesirine
RxNorm normalized name: Loncastuximab tesirine
DrugBank: Loncastuximab tesirine (DB16222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loncastuximab tesirine (all doses)
Trial: 31685491
Drug: Loncastuximab tesirine
RxNorm normalized name: Loncastuximab tesirine
DrugBank: Loncastuximab tesirine (DB16222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loncastuximab tesirine at doses ≥150 μg/kg
Trial: 31686036
Drug: Atezolizumab (neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab (neoadjuvant treatment)
Trial: 31687203
Drug: 1 dose
RxNorm normalized name: Ribose 3 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of Ranibizumab
Trial: 31687203
Drug: 3 loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 loading doses of Ranibizumab
Trial: 31688526
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further prolapse treatment
Trial: 31689155
Drug: DSTP3086S (2.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DSTP3086S (2.4 mg/kg once every 3 weeks)
Trial: 31689155
Drug: DSTP3086S (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DSTP3086S (doses > 2 mg/kg once every 3 weeks)
Trial: 31689155
Drug: DSTP3086S (weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DSTP3086S (weekly dosing)
Trial: 31690286
Drug: Hyperbaric Oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric Oxygen Therapy (HBOT) - 100% oxygen at 2 atm absolute (ATA) for 90 minutes, 20 sessions for 5 days per week, followed by a second cycle of 20 sessions after 1 week of suspension.
Trial: 31690697
Drug: Anti-FGFR3 antibodies
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-FGFR3 antibodies positive patients (65 out of 426)
Trial: 31690697
Drug: Anti-FGFR3 antibodies
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-FGFR3 antibodies negative patients (361 out of 426)
Trial: 31693389
Drug: Sound Production
RxNorm normalized name: IPM Wound Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sound Production Treatment (SPT)
Trial: 31693535
Drug: Nebivolol as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol as monotherapy in de novo patients
Trial: 31693535
Drug: Nebivolol as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol as add-on therapy to existing antihypertensives
Trial: 31694860
Drug: Dietary patterns
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary patterns of insulin pump users
Trial: 31694860
Drug: Dietary patterns
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary patterns of multiple daily injection users
Trial: 31695439
Drug: Single-use autoinjector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-use autoinjector (AI) for benralizumab 30 mg
Trial: 31697308
Drug: BMS-986156 monotherapy
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BMS-986156 monotherapy
Trial: 31699157
Drug: Automated tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated tablet audiometer
Trial: 31699157
Drug: Tablet audiometer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet audiometer for monosyllabic word recognition testing
Trial: 31699157
Drug: Automated tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated tablet audiometric evaluation
Trial: 31699278
Drug: Women with
RxNorm normalized name: Arthricare for Women Moisturizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women with de novo heart failure undergoing reperfusion therapy